Cancer genome: distinguishing causation from selection by age
Hidden dilemma in cancer genome research
In cancer genome analyses, it has been difficult to determine whether frequently observed mutations are true causative events that drive cancer or merely mutations that increase in frequency because they confer a selective advantage. Prior studies have often conflated these two possibilities, making it challenging to confidently identify genuine driver mutations.
Age‑based mathematical model that resolves causation
The research team constructed a mathematical model using age as a key variable and simultaneously analyzed large‑scale sequencing data from tumors and matched normal tissues. This approach quantitatively separated mutations that expand clonally in healthy tissue with age from those that are truly oncogenic, allowing clear discrimination between driver and passenger alterations.
Implications for future therapy and screening
Incorporating the age‑specific behavior of mutations into cancer risk assessment enables more precise risk prediction. Ultimately, this can inform personalized screening and prevention strategies, improve early detection rates, and reduce unnecessary overtreatment.
Nature Genetics, Published online: 05 May 2026; doi:10.1038/s41588-026-02593-z Mutations may be enriched in tumor samples because they promote carcinogenesis or because they promote clonal expansions in healthy tissue. This study mathematically disentangles these two possibilities by analyzing tumor and normal tissue sequencing datasets.
This study resolves the fundamental problem of distinguishing whether mutations commonly observed in cancer tissues are true causes of malignancy or simply reflect age‑related clonal expansion in healthy tissue. By evaluating mutations in the context of age, we can now achieve more accurate cancer risk prediction and design personalized screening strategies.